Eli Lilly's Weight Loss Pill: Clinical Trials Show 29% Reduction

New data indicates that Eli Lilly's investigational oral medication, orforglipron, produced considerable weight loss in clinical studies. This offers a potential new treatment avenue for individuals grappling with obesity and associated health issues. The medication is anticipated to be available next year.

New data reveals that orforglipron, Eli Lilly's oral weight-loss drug candidate, exhibited significant weight reduction in clinical studies, presenting a possible new avenue for those struggling with obesity and associated conditions. The drug is anticipated to be available in 2024.

On Thursday, December 7, 2023, Eli Lilly revealed that its experimental oral drug, orforglipron, resulted in weight loss of up to 29% during clinical trials. The clinical trials included participants who were obese or overweight and had at least one weight-related health condition. The most substantial weight reduction was observed in patients receiving the highest dose of orforglipron.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

The drug functions by activating the GLP-1 receptor, akin to widely used injectable weight-loss drugs like Wegovy and Mounjaro, both also manufactured by Eli Lilly. Health tracking apps like Shotlee can help monitor progress with such medications. However, orforglipron is administered orally, potentially providing a more convenient option for patients.

Source Information

Originally published by News Directory 3.Read the original article →

Keep exploring

More on orforglipron

Articles covering orforglipron dosing, side effects, and clinical updates.

Weight Loss & Metabolic Health

Wegovy Pill Launch: Why 80% of Patients Are Choosing Oral Semaglutide

The launch of the Wegovy pill marks a pivotal shift in obesity treatment. With 80% of new users being first-time patients, oral semaglutide is overcoming historical barriers to care.

9 min read

Same topic: weight loss

All weight loss articles →

Health & Wellness

Wegovy, Zepbound & More: Hers Makes GLP-1s Accessible from $39

The journey to weight loss can be challenging, and for many, advanced medications like GLP-1 injectables offer a crucial pathway. However, their high cost often presents a significant barrier. Hers is changing this landscape by making popular GLP-1 and other weight loss treatments more accessible and affordable than ever before.

7 min read

Medical News

Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise

Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.

7 min read

Medical Insights

Beyond GLP-1s: Unlocking Better Diabetes Control with Korlym

For individuals struggling with difficult-to-control type 2 diabetes and weight management, even powerful GLP-1 medications might not be enough. New research highlights the significant role of hypercortisolism and the promising potential of Korlym in optimizing treatment outcomes.

6 min read

More in Health

Medical News & Insights

Oral Wegovy's Record-Breaking Launch: The New Era of Needle-Free Weight Loss

Novo Nordisk's Wegovy oral formulation has achieved unprecedented prescription rates, marking a pivotal shift in obesity care and intensifying competition with Eli Lilly.

8 min read

Health & Wellness

Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?

Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.

7 min read

Health & Wellness

Beyond Ozempic: A New Pill Targets Fat Metabolism Without Appetite Loss

A groundbreaking pill developed by researchers at Karolinska Institutet and Stockholm University offers a new avenue for treating type 2 diabetes and obesity. Unlike injectable GLP-1 agonists, this oral medication targets muscle metabolism to enhance fat burning and improve blood sugar control, aiming to circumvent common side effects.

7 min read